<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>10(8)</volume><submitter>Miyai M</submitter><pubmed_abstract>Comprehensive immunological evaluation is crucial for monitoring patients undergoing antigen-specific cancer immunotherapy. The identification and quantification of T cell responses is most important for the further development of such therapies. Using well-characterized clinical samples from a high responder patient (TK-f01) in an NY-ESO-1f peptide vaccine study, we performed high-throughput T cell receptor β-chain (TCRB) gene next generation sequencing (NGS) to monitor the frequency of NY-ESO-1-specific CD8+ T cells. We compared these results with those of conventional immunological assays, such as IFN-γ capture, tetramer binding and limiting dilution clonality assays. We sequenced human TCRB complementarity-determining region 3 (CDR3) rearrangements of two NY-ESO-1f-specific CD8+ T cell</pubmed_abstract><journal>PloS one</journal><pagination>e0136086</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4546392</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Detection and Tracking of NY-ESO-1-Specific CD8+ T Cells by High-Throughput T Cell Receptor β (TCRB) Gene Rearrangements Sequencing in a Peptide-Vaccinated Patient.</pubmed_title><pmcid>PMC4546392</pmcid><pubmed_authors>Matsushita H</pubmed_authors><pubmed_authors>Miyai M</pubmed_authors><pubmed_authors>Eikawa S</pubmed_authors><pubmed_authors>Nakajima J</pubmed_authors><pubmed_authors>Hosoi A</pubmed_authors><pubmed_authors>Nakayama E</pubmed_authors><pubmed_authors>Iino T</pubmed_authors><pubmed_authors>Isobe M</pubmed_authors><pubmed_authors>Uenaka A</pubmed_authors><pubmed_authors>Kakimi K</pubmed_authors><pubmed_authors>Udono H</pubmed_authors></additional><is_claimable>false</is_claimable><name>Detection and Tracking of NY-ESO-1-Specific CD8+ T Cells by High-Throughput T Cell Receptor β (TCRB) Gene Rearrangements Sequencing in a Peptide-Vaccinated Patient.</name><description>Comprehensive immunological evaluation is crucial for monitoring patients undergoing antigen-specific cancer immunotherapy. The identification and quantification of T cell responses is most important for the further development of such therapies. Using well-characterized clinical samples from a high responder patient (TK-f01) in an NY-ESO-1f peptide vaccine study, we performed high-throughput T cell receptor β-chain (TCRB) gene next generation sequencing (NGS) to monitor the frequency of NY-ESO-1-specific CD8+ T cells. We compared these results with those of conventional immunological assays, such as IFN-γ capture, tetramer binding and limiting dilution clonality assays. We sequenced human TCRB complementarity-determining region 3 (CDR3) rearrangements of two NY-ESO-1f-specific CD8+ T cell</description><dates><release>2015-01-01T00:00:00Z</release><publication>2015</publication><modification>2025-04-04T12:39:25.057Z</modification><creation>2019-03-26T23:35:27Z</creation></dates><accession>S-EPMC4546392</accession><cross_references><pubmed>26291626</pubmed><doi>10.1371/journal.pone.0136086</doi></cross_references></HashMap>